Clinical Report: Impact of Cushing Syndrome Treatment on Lipid Abnormalities

Overview

This systematic review and meta-analysis of 29 studies demonstrates that treatment of Cushing syndrome (CS) significantly reduces serum total cholesterol, LDL cholesterol, and triglycerides, with no significant change in HDL cholesterol. Additionally, treatment improves glucose metabolism and anthropometric measures, highlighting its beneficial metabolic effects.

Background

Cushing syndrome is characterized by chronic glucocorticoid excess leading to metabolic disturbances including visceral obesity, insulin resistance, hyperglycemia, hypertension, and dyslipidemia. Dyslipidemia in CS contributes to increased cardiovascular mortality, yet its prevalence and management remain variably defined. Treatments for CS include surgical and pharmacological approaches, which may differentially affect lipid profiles. Understanding the impact of CS treatment on lipid abnormalities is critical given the high cardiovascular risk in this population.

Data Highlights

Key Findings

• Treatment of CS significantly decreases serum total cholesterol by approximately 26.5 mg/dL.
• LDL cholesterol levels decrease by about 18.4 mg/dL following CS treatment.
• Triglyceride levels are reduced by nearly 17.8 mg/dL after treatment.
• No significant change is observed in HDL cholesterol levels post-treatment.
• Greater reductions in total cholesterol occur in patients with adrenal hypercortisolism, those treated with steroidogenesis inhibitors, and with treatment durations of 12 months or longer.
• CS treatment also significantly improves blood glucose levels, body mass index, waist circumference, and insulin resistance index.

Clinical Implications

Clinicians should monitor lipid profiles in patients with Cushing syndrome both at diagnosis and during follow-up, as treatment leads to meaningful improvements in atherogenic lipid parameters. The choice of treatment modality and duration may influence lipid outcomes, with steroidogenesis inhibitors and longer treatment durations associated with greater lipid reductions. These metabolic improvements may contribute to lowering cardiovascular risk, underscoring the importance of comprehensive management of CS.

Conclusion

Treatment of Cushing syndrome results in significant improvements in serum lipid abnormalities and metabolic parameters, potentially reducing cardiovascular risk. Further research is needed to confirm whether these biochemical improvements translate into decreased incidence of major cardiovascular events.

References

1. Systematic Review and Meta-Analysis, 2024 -- Impact of Cushing Syndrome Treatment on Lipid Abnormalities